谢欣，女，医学博士/博士后，副高级职称，硕士研究生导师。四川省学术和技术带头人后备人选、“双带头人”、省级创新创业计划指导教师、不列颠哥伦比亚大学访问学者、四川大学访问学者。

主要研究方向：（1）中药药效物质作用机制及构效关系；（2）基于中药药效物质的创新药物发现。

先后主持国家自然科学基金、中国博士后科学基金特别资助项目、中国博士后科学基金面上项目及多项省级、校级课题等科研项目10余项。相关成果发表在Signal Transduct Target Ther、Eur J Med Chem、J Adv Res、Chinese Chem Lett、Org Chem Front、Chem Commun等国际权威学术刊物上，共计发表SCI收录论文20余篇，SCI总引用次数400余次。以第一作者和通讯作者身份发表SCI论文15篇（IF>30的1篇，IF>5的13篇），包含一区论文8篇，自然指数（Nature Index）收录期刊1篇，ESI高被引论文1篇（引用次数已达100余次）；最高影响因子38.104，累计影响因子122.114。获得国家授权发明专利5项。科研成果获“四川省科技进步一等奖”。

联系方式：xiexin@cdutcm.edu.cn

部分负责基金项目：

（1）国家自然科学基金委员会青年基金，82104376，钩吻生物碱作用HSP90介导PI3K/Akt/mTOR通路调控肝癌细胞程序性死亡的作用机制与构效关系研究，2022-01至2024-12，负责人

（2）中国博士后基金科学基金会特别资助项目（站中），2020T1330273，基于多层次化学结构特征的狗牙花单萜吲哚类生物碱抗肿瘤构效关系研究，2020-07至2022-06，负责人

（3）中国博士后基金科学基金会面上项目，2020M673295，基于系统生物学和分子对接的民族药生物碱抗肿瘤药效物质发现及作用机制研究，2020-01至2021-12，负责人

（4）四川省科技厅应用基础项目，2022NSFSC0626，基于有毒中药胡蔓藤抗肿瘤作用靶点的精准构效关系研究及先导药物发现，2022-01至2023-12，负责人

（5）四川省科技厅科技创新创业苗子工程项目，2017049，基于系统生物学的计算机辅助药物设计研究白及茋类成分的抗肿瘤活性，2017-09至2018-09，负责人

（6）威尼斯98488，“杏林学者”青基人才专项，QJRC2017049，基于整合策略和空间构型的胡蔓藤生物碱“构-效-毒”关系研究，2022-10至2025-10，负责人

（7）威尼斯98488，"杏林学者"优秀人才计划项目，YXRC2019004，基于整合药理学策略的苦参生物碱治疗非小细胞肺癌的药效物质研究，2019-09至2021-08，负责人

部分代表性成果：

（1） Xin Xie, Tingting Yu, Xiang Li, Nan Zhang, Leonard J Foster, Cheng Peng*, Wei Huang*, Gu He*. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials. Signal Transduction and Targeted Therapy, 2023, accepted. SCI一区，IF: 39.3

（2） Zhaoping Pan, Yi Chen, Haiying Pang, Xiaoyun Wang, Yuehua Zhang, Xin Xie*, Gu He*. Design, synthesis, and biological evaluation of novel dual inhibitors of heat shock protein 90/mammalian target of rapamycin (Hsp90/mTOR) against bladder cancer cells. European Journal of Medicinal Chemistry, 2022, 242:114674. SCI一区，IF: 7.088

（3） Xin Xie, Nan Zhang, Xiang Li, He Huang, Cheng Peng, Wei Huang, Leonard J. Foster*, Gu He*, Bo Han*. Small-molecule dual inhibitors targeting heat shock protein 90 for cancer targeted therapy. Bioorganic Chemistry, 2023, 139, 106721. SCI一区，IF: 5.307

（4） Xin Xie, Shan-Shan Xiong, Xiang Li, He Huang, Fengbo Wu, Peng-Fei Shen, Cheng Peng*, Gu He*, Bo Han*. Design and organocatalytic synthesis of spirooxindole-cyclopentene-isoxazole hybrids as novel MDM2-p53 inhibitors. Organic Chemistry Frontiers, 2021, 8: 1836-1843. SCI一区，IF: 5.456

（5） Xin Xie, Wei Huang, Cheng Peng^*, Bo Han^*. Organocatalytic asymmetric synthesis of six-membered carbocycle-based spiro compounds. Advanced Synthesis & Catalysis, 2018, 360: 194-228. SCI一区，IF: 5.981 （ESI高被引论文）

（6） Xin Xie, Cheng Peng^*, Gu He, Haijun Leng, Biao Wang, Wei Huang^*, Bo Han^*. Asymmetric synthesis of a structurally and stereochemically complex spirooxindole pyran scaffold through an organocatalytic multicomponent cascade reaction. Chemical Communications, 2012, 48: 10487-10489. SCI二区，IF: 6.065（Nature Index期刊，封底文章）

（7） Lian Wang^#, Xin Xie^#, Bowen Ke, Wei Huang*, Xian Jiang, Gu He*. Recent advances on endogenous gasotransmitters in inflammatory dermatological disorders. Journal of Advanced Research, 2022, 38: 261-274. SCI一区，IF: 12.822（8） Jun Mu^#, Xin Xie^#, Shanshan Xiong, Yuehua Zhang, Yuting Wang, Qian Zhao, Hongping Zhu, Wei Huang*, Gu He*. Discovery of spirooxindole-ferrocene hybrids as novel MDM2 inhibitors. Chinese Chemical Letters, 2021, 32:1897-1901. SCI一区，IF: 8.455

（9） Xin Xie, Li Xiang, Cheng Peng*, Bo Han*. Catalytic Asymmetric Synthesis of spiropyrazolones and their application in medicinal chemistry. Chemical Record, 2019, 19: 2209-2235. SCI二区，IF: 6.935

（10） Bo Han^#, Xin Xie^#, Wei Huang, Xiang Li, Lei Yang, Cheng Peng*. Organocatalytic cascade Morita-Baylis-Hillman/Michael/acetalization sequence: procedure-controlled diastereodivergence in the asymmetric synthesis of fully functionalized tetrahydropyrans. Advanced Synthesis & Catalysis, 2014, 356: 3676-3682. SCI一区，IF: 5.981

（11） Xiang Li, Jia-Jia Geng-Ji, Yunyun Quan, Luming Qi, Sun Qiang, Qun Huang, Hai-Mei Jiang, Hongmei Liu*, Xin Xie*. Role of Potential Bioactive Metabolites from Traditional Chinese Medicine for Type 2 Diabetes Mellitus: An Overview. Frontiers in Pharmacology, 2022, published online, doi: 10.3389/fphar.2022.1023713. SCI二区，IF: 5.988

（12） Hongmei Liu*, Yunyun Quan, Long Xie, Xiang Li*, Xin Xie*. The cascade [1,5]-hydride shift/intramolecular C(sp³)-H activation: A powerful approach to the construction of spiro-tetrahydroquinoline skeleton. Frontiers in Chemistry, 2022, 13: 840934. SCI二区，IF: 5.545

（13） Mengting Li, Long Xie, Haimei Jiang, Qun Huang, Rongsheng Tong, Xiang Li*, Xin Xie*, Hongmei Liu*. Role of licochalcone A in potential pharmacological therapy: A review. Frontiers in Pharmacology, 2022, 13: 878776. SCI二区，IF: 5.988

（14） Xiang Li, Chuntao Zhang, Wei Ma, Xin Xie*, Qun Huang*. Oridonin: A Review of Its Pharmacology, Pharmacokinetics and Toxicity. Frontiers in Pharmacology 2021, 12: 645824. SCI二区，IF: 5.988